ANSWER: B

Rationale:

This question asked you to identify the primary intracellular consequence of Gi/Go coupling at the mu-opioid receptor that would be eliminated when that coupling is selectively blocked. Option B is correct: the principal effector mechanism of Gi/Go activation at opioid receptors is inhibition of adenylyl cyclase, the enzyme that synthesizes cyclic AMP (cAMP) from ATP. When Gi is blocked, this suppression of cAMP production is lost, and downstream cAMP-dependent signaling (including PKA-mediated phosphorylation of ion channels and transcription factors) is no longer inhibited — this is the molecular basis of the cellular-level analgesia and also contributes to the cAMP rebound (adenylyl cyclase superactivation) seen during opioid withdrawal.

• Option A: Option A is incorrect: phospholipase C activation and IP3 production are characteristics of Gq-coupled receptors (such as muscarinic M1/M3, alpha-1 adrenergic, and histamine H1), not the Gi/Go pathway that opioid receptors predominantly engage.
• Option C: Option C is incorrect: opioids do not produce analgesia by directly blocking voltage-gated sodium channels in the manner of local anesthetics; their primary mechanism involves G-protein-mediated modulation of adenylyl cyclase, potassium channels, and calcium channels — not direct sodium channel blockade.
• Option D: Option D is incorrect: GRK-mediated receptor phosphorylation is a consequence of receptor activation and occurs independently of Gi coupling; GRKs act on the activated receptor regardless of whether downstream Gi signaling is intact, and blocking Gi would not increase GRK activity.
• Option E: Option E is incorrect: beta-arrestin recruitment is promoted by GRK-mediated phosphorylation of the activated receptor and is not a direct product of Gi coupling; selectively blocking Gi does not upregulate beta-arrestin-2 recruitment — in fact, beta-arrestin recruitment proceeds through a parallel pathway that can occur even when G-protein signaling is disrupted.

ANSWER: D

Rationale:

This question asked you to identify the primary postsynaptic ionic mechanism by which MOR activation hyperpolarizes dorsal horn neurons. Option D is correct: MOR couples through Gi/Go to directly activate G-protein-coupled inwardly rectifying potassium (GIRK) channels via release of the Gbetagamma subunit. GIRK channel opening increases membrane conductance to potassium, driving the membrane potential toward the potassium equilibrium potential (approximately -90 mV in most neurons), which is well below the action potential threshold. This hyperpolarization reduces neuronal excitability and suppresses transmission of nociceptive signals in the dorsal horn — a mechanism shared by many inhibitory GPCRs including GABA-B receptors.

• Option A: Option A is incorrect: while Gi/Go signaling can inhibit voltage-gated calcium channels (particularly N- and P/Q-type), this is primarily a presynaptic mechanism relevant to reducing neurotransmitter release from primary afferent terminals, not the primary mechanism of postsynaptic hyperpolarization; L-type calcium channels play a minor role in this context.
• Option B: Option B is incorrect: HCN channels are regulated by cyclic nucleotides and contribute to pacemaker currents in cardiac and certain neuronal cells; while cAMP suppression by Gi can modulate HCN channel activity, this is not the primary or direct postsynaptic hyperpolarizing mechanism of opioid receptor activation in dorsal horn neurons.
• Option C: Option C is incorrect: voltage-gated Kv channels accelerate repolarization following action potentials but are not directly gated by G-protein betagamma subunits; they are not the mechanism responsible for the sustained hyperpolarization produced by opioid receptor activation.
• Option E: Option E is incorrect: opioids do not directly close voltage-gated sodium channels to raise the action potential threshold in the manner of local anesthetics; their postsynaptic hyperpolarizing effect is mediated through GIRK channel activation, not sodium channel modulation.

ANSWER: A

Rationale:

This question asked you to identify the molecular consequence of GRK-mediated phosphorylation of the activated MOR. Option A is correct: GRK2 and GRK3 phosphorylate serine and threonine residues on the intracellular loops and C-terminus of the activated MOR, creating docking sites for beta-arrestin proteins. Beta-arrestin binding sterically occludes the intracellular surface of the receptor that normally contacts Gi/Go, preventing further G-protein coupling — this is the mechanism of acute desensitization. Beta-arrestin also serves as a scaffold for endocytic machinery including clathrin and AP2, directing the receptor into clathrin-coated pits for internalization. Internalized receptors may be dephosphorylated and recycled (resensitization) or degraded (downregulation).

• Option B: Option B is incorrect: GRK-mediated phosphorylation does not activate adenylyl cyclase; in fact, the opposite is true during receptor activation — Gi alpha suppresses adenylyl cyclase. The cAMP rebound (superactivation) that follows opioid withdrawal is a separate adaptive phenomenon involving upregulation of adenylyl cyclase isoforms, not an acute consequence of GRK phosphorylation.
• Option C: Option C is incorrect: GRK phosphorylation does not cause immediate proteasomal degradation after a single activation event; receptor fate after internalization depends on subsequent sorting decisions in endosomes, and the predominant outcome is recycling back to the membrane (resensitization) rather than immediate degradation, though prolonged or heavy receptor activation can eventually lead to lysosomal downregulation.
• Option D: Option D is incorrect: GPCRs do not switch their G-protein coupling class as a result of phosphorylation; the receptor's selectivity for Gi/Go versus Gq is determined by its intracellular loop structure and is not altered by GRK-mediated phosphorylation, which instead terminates rather than redirects G-protein signaling.
• Option E: Option E is incorrect: opioid receptors are GPCRs and do not function as ion channels; they do not contain an intrinsic ion-conducting pore, and no phosphorylation event converts a GPCR into a ligand-gated ion channel.

ANSWER: C

Rationale:

This question asked you to identify the primary presynaptic mechanism by which MOR activation on primary afferent terminals reduces neurotransmitter release. Option C is correct: the Gbetagamma subunit released upon Gi/Go activation directly inhibits voltage-gated calcium channels, predominantly N-type (Cav2.2) and P/Q-type (Cav2.1) channels that are responsible for the calcium influx that triggers vesicular exocytosis. By reducing calcium entry into the presynaptic terminal in response to an action potential, opioids decrease the release of pain-transmitting neurotransmitters — glutamate, substance P, and calcitonin gene-related peptide (CGRP) — into the dorsal horn synaptic cleft, diminishing the postsynaptic nociceptive signal.

• Option A: Option A is incorrect: while GIRK channel activation does contribute to hyperpolarization, GIRK-mediated effects are predominantly a postsynaptic mechanism in dorsal horn neurons; presynaptic terminals are generally compact structures where calcium channel inhibition rather than sustained GIRK-mediated hyperpolarization is the dominant opioid mechanism for reducing transmitter release.
• Option B: Option B is incorrect: the Gi alpha-subunit does not directly bind to SNARE proteins to prevent vesicle fusion; this is not an established mechanism of opioid-mediated presynaptic inhibition — the calcium channel inhibition mechanism via Gbetagamma is the well-characterized pathway for reducing exocytosis.
• Option D: Option D is incorrect: MOR activation suppresses adenylyl cyclase and reduces cAMP through Gi coupling — it does not activate adenylyl cyclase; elevated cAMP actually promotes neurotransmitter release in many neuronal preparations by activating PKA and phosphorylating release machinery, so this option describes both the wrong direction of cAMP change and a non-existent stabilization mechanism.
• Option E: Option E is incorrect: presynaptic voltage-gated sodium channel blockade is the mechanism of local anesthetics, not opioids; opioids act downstream of action potential propagation — they allow the action potential to arrive at the terminal but reduce the calcium-triggered release event itself.

ANSWER: E

Rationale:

This question asked you to trace the supraspinal descending inhibitory cascade initiated by PAG opioid receptor activation. Option E is correct: MOR activation in the PAG acts primarily on inhibitory GABAergic interneurons — it suppresses their activity, thereby disinhibiting PAG projection neurons (a disinhibition mechanism rather than direct excitation). These disinhibited PAG output neurons activate the rostral ventromedial medulla (RVM), a relay structure that sends descending projections to the spinal cord dorsal horn via noradrenergic pathways (from the locus coeruleus and A7 cell group) and serotonergic pathways (from the nucleus raphe magnus). These descending fibers inhibit nociceptive transmission in the dorsal horn through release of norepinephrine and serotonin onto dorsal horn neurons. This multi-synapse descending inhibitory circuit is the principal supraspinal mechanism of opioid analgesia.

• Option A: Option A is incorrect: PAG output to the dorsal horn is not direct glutamatergic in the classical sense described; the pathway relays through the RVM and utilizes monoaminergic (noradrenergic and serotonergic) rather than glutamatergic neurotransmission as its primary inhibitory mechanism at the spinal level.
• Option B: Option B is incorrect: the locus coeruleus is a noradrenergic, not serotonergic, nucleus; serotonergic descending input originates from the nucleus raphe magnus; additionally, 5-HT3 receptors are ionotropic cation channels that are excitatory, not the primary mechanism of descending serotonergic inhibition in the dorsal horn.
• Option C: Option C is incorrect: MOR activation in the PAG does not inhibit the nucleus raphe magnus — instead, PAG output activates the RVM (which includes the raphe magnus), which then sends inhibitory signals to the dorsal horn; the net effect is increased descending inhibition, not paradoxical increased nociception.
• Option D: Option D is incorrect: spinothalamic tract neurons are ascending projection neurons that transmit nociceptive information; descending norepinephrine acts on alpha-2 adrenergic receptors on dorsal horn neurons to inhibit, not depolarize, nociceptive transmission — the direction of the effect described in this option is reversed.

ANSWER: B

Rationale:

This question asked you to explain the mechanistic logic linking morphine's poor receptor internalization to its greater tolerance liability. Option B is correct: the internalization-recycling hypothesis proposes that receptor internalization, followed by dephosphorylation in endosomes and recycling back to the plasma membrane, is a resensitization mechanism that restores receptor responsiveness. When morphine's weak beta-arrestin recruitment results in poor internalization, receptors that have been desensitized by GRK phosphorylation are not efficiently cycled through this resensitization pathway — they accumulate on the cell surface in a desensitized, uncoupled state. The net result is progressive loss of functional receptor signaling with continued morphine exposure, contributing to tolerance. Etorphine, by robustly promoting internalization and recycling, allows the receptor to reset, potentially limiting the accumulation of desensitized surface receptors.

• Option A: Option A is incorrect: morphine's poor internalization is not explained by lower receptor affinity — morphine is in fact a high-affinity MOR agonist; the difference lies specifically in its weak ability to recruit beta-arrestin relative to other full agonists such as etorphine or DAMGO (D-Ala2-N-MePhe4-Gly-ol enkephalin), even at concentrations that produce robust Gi activation.
• Option C: Option C is incorrect: morphine, like etorphine, signals through Gi/Go rather than Gq; opioid receptor coupling to Gq is not a standard feature of MOR pharmacology, and IP3-mediated calcium release is not the driver of receptor internalization — beta-arrestin recruitment triggered by GRK phosphorylation is the relevant mechanism.
• Option D: Option D is incorrect: MOR tolerance is not primarily explained by transcriptional upregulation of receptor gene expression producing non-functional protein; the established cellular mechanisms involve receptor desensitization, phosphorylation, and internalization dynamics, as well as downstream adaptations such as adenylyl cyclase superactivation — not transcriptional overproduction of dysfunctional receptor.
• Option E: Option E is incorrect: internalized receptors are predominantly recycled back to the membrane (resensitization), not permanently degraded; permanent degradation (downregulation via lysosomal targeting) does occur but is not the primary fate of internalized receptors, and the proposed benefit of internalization in this hypothesis is resensitization through recycling, not permanent receptor elimination.

ANSWER: A

Rationale:

This question asked you to explain why intrathecal morphine requires 100- to 1000-fold lower doses than systemic morphine for equivalent analgesia. Option A is correct: the dose advantage of intrathecal delivery is primarily a pharmacokinetic one — direct delivery into the cerebrospinal fluid places morphine immediately adjacent to opioid receptors in the dorsal horn (particularly laminae I and II), eliminating the requirement to achieve and sustain systemic plasma concentrations high enough to drive adequate drug across the blood-brain barrier and distribute through spinal cord parenchyma from the vasculature. Because intrathecal drug reaches its target receptors with essentially 100% efficiency at the spinal level, dramatically less total drug is needed. This is also why intrathecal opioids produce relatively segmental analgesia — drug concentration is highest at the level of administration — though rostral spread in CSF does occur and can reach brainstem respiratory centers.

• Option B: Option B is incorrect: morphine is not converted by CSF into a higher-affinity metabolite; while morphine-6-glucuronide (an active metabolite) is produced hepatically and has significant analgesic activity, this conversion does not occur in CSF, and no 100-fold potency-enhancing CSF transformation of morphine has been described.
• Option C: Option C is incorrect: there is no pharmacologically distinct high-affinity spinal MOR isoform that accounts for the dose difference; the MOR expressed in spinal cord dorsal horn is the same receptor as in supraspinal and peripheral sites, and the dose advantage is explained by access and distribution rather than receptor biology.
• Option D: Option D is incorrect: while bypassing first-pass metabolism does increase bioavailability, morphine given intravenously has already bypassed first-pass metabolism entirely — the comparison in clinical practice is intrathecal versus intravenous, not oral, so first-pass metabolism does not account for the dose difference in this context; the relevant explanation is direct spinal delivery rather than metabolic considerations.
• Option E: Option E is incorrect: morphine behaves as a full MOR agonist whether administered intrathecally or systemically; its intrinsic efficacy at MOR does not change based on route of administration, and partial agonism is a property of specific ligands such as buprenorphine, not a route-dependent property of morphine.

ANSWER: C

Rationale:

This question asked you to identify the primary brainstem site and mechanism of opioid-induced respiratory rate suppression. Option C is correct: the pre-Botzinger complex (preBotC) is the rhythmogenic kernel of the mammalian respiratory rhythm generator, located in the ventrolateral medulla. It contains interneurons that fire in a pacemaker-like pattern to generate the respiratory rhythm, and these neurons express high densities of MOR. Opioid activation of MOR in the preBotC directly suppresses the intrinsic pacemaker activity of these respiratory interneurons, reducing the frequency of the rhythm they generate — this is the primary mechanism by which opioids reduce respiratory rate. The clinical presentation of bradypnea with hypercapnia (elevated PaCO2) reflects this central rhythm suppression combined with opioid-mediated blunting of the normal CO2 ventilatory response.

• Option A: Option A is incorrect: the nucleus tractus solitarius processes afferent chemoreceptor and mechanoreceptor input and is involved in the CO2 ventilatory response, but the primary mechanism of opioid-induced respiratory rate reduction is not paradoxical enhancement of inhibitory chemoreceptor feedback via the NTS — it is direct suppression of the rhythm-generating preBotC neurons.
• Option B: Option B is incorrect: while the locus coeruleus does have noradrenergic projections that influence breathing, it is not the primary site of opioid-induced respiratory depression; the critical rhythmogenic target is the preBotC in the ventrolateral medulla, not the noradrenergic locus coeruleus in the dorsal pons.
• Option D: Option D is incorrect: the pneumotaxic center (parabrachial nucleus in the upper pons) modulates the inspiratory-expiratory switch and influences tidal volume more than respiratory rate; opioid effects on respiratory rate are mediated primarily through the preBotC, and prolonged inspiratory holds are not the characteristic presentation of opioid-induced respiratory depression, which typically manifests as slow, shallow breathing.
• Option E: Option E is incorrect: while opioids do suppress peripheral carotid body chemoreceptor activity and blunt the hypoxic ventilatory response, this is not the sole mechanism of opioid-induced respiratory depression; the primary central mechanism via the preBotC is essential and would produce respiratory depression even in the absence of peripheral chemoreceptor input, as demonstrated by experiments in decerebrate and peripherally denervated animal preparations.

ANSWER: D

Rationale:

This question asked you to explain the differential development of tolerance to opioid analgesia versus opioid-induced constipation. Option D is correct: the distinction between analgesic tolerance and persistent OIC reflects differential adaptive capacity at the receptor and cellular level across CNS versus enteric nervous system (ENS) compartments. In CNS pain-modulating circuits — including the periaqueductal gray, rostral ventromedial medulla, and spinal cord dorsal horn — sustained opioid receptor activation produces robust desensitization (via GRK phosphorylation and beta-arrestin recruitment), receptor downregulation, adenylyl cyclase superactivation, and synaptic plasticity changes, all of which progressively attenuate the analgesic response. Enteric MOR-expressing neurons, while subject to similar molecular mechanisms in principle, undergo comparatively less receptor desensitization and neuroadaptation with ongoing opioid exposure, so the inhibitory effect on intestinal motility is substantially maintained — OIC does not meaningfully diminish with chronic therapy, in sharp clinical contrast to analgesia.

• Option A: Option A is incorrect: the enteric nervous system does robustly express MOR, and OIC is indeed a MOR-mediated effect; peripherally restricted MOR antagonists such as methylnaltrexone and naloxegol, which do not cross the blood-brain barrier, reverse OIC specifically by blocking enteric MOR — demonstrating that OIC is MOR-dependent.
• Option B: Option B is incorrect: the blood-brain barrier does not progressively exclude morphine over time with chronic exposure; if anything, inflammatory or pathological conditions can increase blood-brain barrier permeability, and morphine's CNS access is not diminished by chronic dosing — the basis of analgesic tolerance is receptor-level and synaptic adaptation, not pharmacokinetic exclusion.
• Option C: Option C is incorrect: while morphine-6-glucuronide (M6G) is an active analgesic metabolite, OIC is not primarily attributed to M6G accumulation; the direct action of morphine (and its metabolites) on enteric MOR mediates constipation, and the differential tolerance pattern is not explained by metabolite-specific receptor behavior.
• Option E: Option E is incorrect: patients on sustained-release oral morphine formulations maintain relatively constant plasma levels and sustained enteric MOR occupancy throughout the day — the premise that enteric receptors are stimulated only intermittently during peak levels does not accurately describe the pharmacokinetics of chronic oral morphine therapy, and intermittent versus continuous stimulation does not explain the differential tolerance profile in this clinical context.

ANSWER: E

Rationale:

This question asked you to identify the mechanism of methadone-induced QTc prolongation and explain why fluconazole co-administration is concerning. Option E is correct: methadone is unique among opioid analgesics in its ability to block hERG (human ether-a-go-go related gene) potassium channels — the channels responsible for the rapid component of the delayed rectifier outward potassium current (IKr) — in ventricular myocytes. IKr is the dominant repolarizing current during phase 3 of the cardiac action potential; its inhibition prolongs action potential duration, which manifests as QTc prolongation on the surface ECG and creates risk for torsades de pointes (TdP), a potentially fatal polymorphic ventricular tachycardia. Fluconazole is a potent inhibitor of CYP3A4, the cytochrome P450 isoenzyme that is the primary route of methadone hepatic metabolism; by inhibiting methadone's clearance, fluconazole raises methadone plasma concentrations substantially, amplifying hERG channel blockade and further prolonging the QTc beyond what methadone alone would produce. This interaction is a clinically important drug-drug interaction requiring close cardiac monitoring or dose adjustment.

• Option A: Option A is incorrect: methadone's QTc-prolonging effect is mediated through hERG potassium channel blockade, not through cardiac MOR-Gi signaling; the MOR is not the relevant cardiac target for this adverse effect, and Gi-mediated suppression of L-type calcium current would shorten rather than lengthen the action potential plateau.
• Option B: Option B is incorrect: methadone's QTc prolongation is due to hERG potassium channel blockade affecting phase 3 repolarization, not sodium channel blockade affecting phase 0; sodium channel blockade widens the QRS complex rather than prolonging the QT interval, which are distinct ECG findings.
• Option C: Option C is incorrect: methadone blocks hERG channels rather than activating them; hERG channel activation would accelerate, not impair, phase 3 repolarization, which would shorten rather than prolong the QTc interval — the option describes the mechanism in reverse.
• Option D: Option D is incorrect: methadone's QTc prolongation is not mediated through alpha-1 adrenergic receptor blockade; while methadone does have some weak alpha-1 blocking properties, this is not the mechanism of its clinically significant QTc prolongation, which is specifically attributed to direct hERG channel blockade; fluconazole does not share this mechanism.

ANSWER: C

Rationale:

This question asked you to explain the mechanistic basis of buprenorphine's ceiling effect for respiratory depression. Option C is correct: buprenorphine is a partial agonist at MOR — it binds with extremely high affinity (Ki approximately 0.1-1 nM, among the highest of any opioid) but has lower intrinsic efficacy (Emax) than full agonists such as morphine or fentanyl. Because it occupies MOR with very high affinity, even relatively modest doses produce high receptor occupancy; however, because its intrinsic efficacy is submaximal, the maximal receptor response it can produce is limited by the partial agonist ceiling. For respiratory depression, which requires a substantial degree of MOR activation at brainstem respiratory centers, this ceiling in receptor activation translates to a ceiling in the respiratory depressant effect regardless of further dose increases. Analgesia, which can be achieved with lower degrees of MOR activation at pain-modulating circuits, continues to increase with dose within the partial agonist ceiling — explaining why buprenorphine provides effective analgesia across a wide dose range while maintaining respiratory safety.

• Option A: Option A is incorrect: buprenorphine does not function as a competitive antagonist at respiratory MOR while acting as a full agonist at pain circuit MOR; different anatomical locations do not express fundamentally different MOR splice variants with opposing pharmacological responses to the same ligand; the ceiling effect is a property of partial intrinsic efficacy at the same receptor.
• Option B: Option B is incorrect: norbuprenorphine is actually an active metabolite of buprenorphine with opioid agonist activity rather than a competitive antagonist; rapid local metabolism to an antagonist metabolite is not the basis of the ceiling effect for respiratory depression.
• Option D: Option D is incorrect: while buprenorphine does have partial agonist and antagonist activity at kappa-opioid receptors, the ceiling for respiratory depression is not mechanistically explained by KOR activation counteracting MOR activation; the ceiling is an intrinsic pharmacodynamic property of buprenorphine's partial agonism at MOR itself.
• Option E: Option E is incorrect: plasma protein binding saturation does not explain the ceiling effect for respiratory depression; buprenorphine's ceiling is a receptor-level pharmacodynamic phenomenon (partial intrinsic efficacy) rather than a pharmacokinetic limitation on drug delivery to the brainstem.

ANSWER: B

Rationale:

This question asked you to define biased agonism at MOR in the context of oliceridine's development and identify its intended therapeutic rationale. Option B is correct: biased agonism (functional selectivity) refers to the ability of a ligand to differentially stabilize distinct receptor conformations that preferentially couple to specific downstream pathways — in the case of MOR, the two major signaling branches are G-protein (Gi/Go) activation and beta-arrestin recruitment. The therapeutic hypothesis behind G-protein-biased MOR agonists is that G-protein signaling is the primary mediator of analgesia, while beta-arrestin recruitment contributes to adverse effects including respiratory depression, constipation, and tolerance development. Oliceridine was designed to preferentially activate Gi/Go signaling while producing relatively less beta-arrestin recruitment compared to morphine. Clinical trials demonstrated that oliceridine produced analgesia with a modestly improved respiratory adverse effect profile, though the magnitude of advantage was limited and the drug remains a restricted agent in current practice.

• Option A: Option A is incorrect: oliceridine crosses the blood-brain barrier and produces central analgesia — it is not a peripherally restricted opioid; peripheral restriction is a separate drug design strategy exemplified by agents such as loperamide (in the GI tract) and naloxegol (a peripherally acting MOR antagonist for OIC), not by biased agonism.
• Option C: Option C is incorrect: oliceridine binds to the orthosteric opioid binding site of MOR, not to a distinct allosteric site; biased agonism refers to differential downstream signaling from the same binding site, not to allosteric versus orthosteric binding location.
• Option D: Option D is incorrect: oliceridine does not require co-activation by endogenous opioid peptides; it is a direct MOR agonist that activates the receptor independently, and biased agonism does not describe a conditional activation mechanism that depends on simultaneous endogenous ligand binding.
• Option E: Option E is incorrect: the mu-1/mu-2 subtype distinction is a historically proposed functional classification that is not pharmacologically validated at the receptor gene level in the way that oliceridine's design was conceived; biased agonism is a signaling pathway concept operating downstream of receptor binding, not a receptor subtype selectivity concept, and oliceridine's development was based on G-protein versus beta-arrestin pathway bias rather than subtype selectivity.

ANSWER: A

Rationale:

This question asked you to identify the mechanisms by which peripheral inflammation enhances the analgesic contribution of peripheral MOR activation. Option A is correct: the upregulation of peripheral opioid analgesia in inflammation involves multiple converging mechanisms. First, inflammatory mediators (prostaglandins, bradykinin, cytokines) increase receptor-G protein coupling efficiency and promote axonal transport and insertion of MOR into the peripheral terminal membrane, increasing the density of functional receptors at the site of injury. Second, inflammation disrupts the perineural barrier (the peripheral analogue of the blood-brain barrier that normally restricts drug access to nerve endings), allowing exogenous opioids to reach peripheral MOR more readily than in non-inflamed tissue. Third, activated immune cells at the site of inflammation (macrophages, lymphocytes, mast cells) release endogenous opioid peptides including beta-endorphin and enkephalins, which activate peripheral MOR to produce endogenous local analgesia — a mechanism that normally does not operate significantly under non-inflammatory conditions. These three mechanisms together explain why peripherally administered or locally delivered opioids produce substantially greater analgesia in inflamed than in normal tissue.

• Option B: Option B is incorrect: while increased blood flow does occur in inflammation, the enhanced peripheral opioid effect is not simply a pharmacokinetic consequence of higher local drug delivery — the receptor-level adaptations described in Option A are the primary mechanisms, and the effect is disproportionate to what increased delivery alone would predict.
• Option C: Option C is incorrect: peripheral MOR does not convert from Gi to Gs coupling under inflammatory conditions; such a receptor coupling class switch has not been established as a mechanism of peripheral opioid analgesia enhancement, and Gs-coupled receptor activation would increase cAMP and promote rather than inhibit nociceptor activity.
• Option D: Option D is incorrect: prostaglandins are inflammatory mediators that sensitize nociceptors by acting on their own receptors (EP receptors) rather than serving as allosteric potentiators at MOR; prostaglandins do not act at MOR binding sites, and the enhanced peripheral opioid effect in inflammation is not explained by prostaglandin-mediated changes in MOR binding affinity.
• Option E: Option E is incorrect: peripheral inflammation does not produce analgesia through downregulation of peripheral MOR expression; peripheral MOR expression is in fact upregulated or maintained (with increased coupling efficiency) in inflamed tissue, and the enhanced opioid effect reflects enhanced receptor function, not receptor loss — receptor downregulation would be expected to reduce, not enhance, peripheral opioid analgesia.